Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | AGXT | P21549 | 1/20 | 0.58 |
| ▸ | LGMN | Q99538 | 2/20 | 0.58 |
| ▸ | KMO | O15229 | 1/20 | 0.57 |
| ▸ | DHFR | P00374 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29371026 | 1.00 | ADRA2C (0.61) | ADRA2CLMNAAGXTLGMNKMO | |
| SCHEMBL6992774 | 1.00 | ADRA2C (0.61) | ADRA2CLMNAAGXTLGMNKMO | |
| Hydrochloric Acid SCHEMBL14742169 | 0.98 | ADRA2C (0.59) | ADRA2CLMNAAGXTLGMNKMO | |
| SCHEMBL14320394 | 0.89 | AGXT (0.56) | ADRA2CLMNAAGXTLGMNKMO | |
| SCHEMBL30706470 | 0.89 | ADRA2C (0.53) | ADRA2CLMNAAGXTLGMNKMO | |
| SCHEMBL27329825 | 0.87 | LMNA (0.71) | LMNAAGXTLGMNKMODHFR | |
| SCHEMBL6942579 | 0.85 | ADRA2C (0.80) | ADRA2CLMNAAGXTMAPTSMN1; SMN2 | |
| SCHEMBL14320480 | 0.84 | JAK2 (0.55) | LMNAAGXTLGMNKMOMAPT | |
| SCHEMBL521012 | 0.84 | AOC3 (0.55) | ADRA2CLMNAAGXTLGMNKMO | |
| SCHEMBL2627250 | 0.83 | ADRA2C (0.71) | ADRA2CLMNAMAPTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 677 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | claimed |
| CN-106152356-A | A kind of band solar panels movable indoor intellectuality humidifier robot control system(RCS) and method of work thereof | 徐州工程学院 | 2016-11-23 | — | — | CN | claimed |
| CN-104672217-A | New linezolid intermediate, preparation method thereof, and linezolid synthesis method | BEIJING ZHONGHE MINJIAN PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-06-03 | — | — | CN | claimed |
| CN-103354809-A | Arylurea compound, intermediate and use thereof | SHANGHAI INST PHARM INDUSTRY | 2013-10-16 | — | — | CN | claimed |
| EP-2323980-B1 | 7-(PIPERAZINE-1-YMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID (PHENYL)-AMIDE DERIVATIVES AND ALLIED COMPOUNDS AS P38 MAP KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2012-02-29 | — | — | EP | claimed |
| JP-2012500835-A | — | — | 2012-01-12 | — | — | JP | claimed |
| EP-2334637-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-06-22 | — | — | EP | claimed |
| EP-2190834-B1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | claimed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | claimed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | claimed |
| WO-2006053227-A2 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | claimed |
| EP-1542982-A1 | HAIR DYES COMPRISING M-PHENYLENEDIAMINE DERIVATIVES AS COUPLING COMPONENTS | Henkel Kommanditgesellschaft auf Aktien (DE) | 2005-06-22 | — | — | EP | claimed |
| US-6812225-B2 | PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | claimed |
| US-20040205903-A1 | Dyeing composition comprising a cationic pyrrolidine-based para-phenylenefiamine, a tertiary para-phenylenediamine and a benzomorpholine coupler, methods and uses | L'OREAL (FR) | 2004-10-21 | — | — | US | claimed |
| WO-2004031164-A1 | HAIR DYES COMPRISING M-PHENYLENEDIAMINE DERIVATIVES AS COUPLING COMPONENTS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2004-04-15 | — | — | WO | claimed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | claimed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040205903-A1 | Dyeing composition comprising a cationic pyrrolidine-based para-phenylenefiamine, a tertiary para-phenylenediamine and a benzomorpholine coupler, methods and uses | CDC73, KRT18, PAH | ADRA2C 1382/4885LMNA 962/4885AGXT 3199/4885 |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | ADRA2C 609/4885LMNA 1934/4885AGXT 2787/4885 |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | ADRA2C 49/4885LMNA 1663/4885AGXT 1084/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | ADRA2C 49/4885LMNA 1808/4885AGXT 943/4885 |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | ADRA2C 3732/4885LMNA 834/4885AGXT 3489/4885 |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | ADRA2C 1238/4885LMNA 4101/4885AGXT 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.